Literature DB >> 15827399

Identification of sentinel lymph node in stage I-II breast cancer with lymphoscintigraphy and surgical gamma probe: comparison of Tc-99m MIBI and Tc-99m sulfur colloid.

P Arcan1, E Ibis, G Aras, R Cam, N O Küçük.   

Abstract

AIM: To evaluate the efficacy of the surgical gamma probe (SGP) after peritumoral injection of Tc-99m MIBI and filtered Tc-99m sulfur colloid (SC) in sentinel lymph node (SLN) detection in stage I and II breast cancer for deciding on the need for axillary dissection.
MATERIALS AND METHODS: Thirty patients with stage I-II breast cancer had peritumoral injection of Tc-99m MIBI (74 MBq/0.2 mL [2 mCi/0.2 mL] at 4 different locations) and 42 different patients had peritumoral injection of filtered Tc-99m sulfur colloid (50 MBq/0.2 mL [1.3 mCi/0.2 mL] at 4 different locations). Anterior, lateral, and anterolateral spot images were acquired at 10, 30, 45, 60, and 120 minutes and 24 hours are injection in 5 patients. During surgery, counts were obtained from the injection site, affected breast tissue, internal mammary, axillary, and supraclavicular regions and the contralateral side using the gamma probe. Peritumoral blue dye was also injected during surgery. The first lymph nodes with counts at least twice the background tissue and/or with blue dye uptake were surgically isolated. Modified radical mastectomy and axillary dissection were performed.
RESULTS: Histopathologic evaluation was made on SLN and other excised tissues. In the Tc-99m sulfur colloid group, lymphatic drainage and lymph nodes were demonstrated with lymphoscintigraphy in 31 of 42 patients. SLN was detected by SGP in 35 of 42 patients. In the Tc-99m MIBI group, lymphatic drainage and lymph nodes were visualized with lymphoscintigraphy in 23 of 30 patients. SLN was detected in 25 of 30 patients with SGP in this group.
CONCLUSION: In patients with stage I-II breast cancer, SLN could be successfully demonstrated with lymphoscintigraphy and SGP by the peritumoral injection of filtered Tc-99m sulfur colloid and Tc-99m MIBI.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15827399     DOI: 10.1097/01.rlu.0000159528.12028.1f

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  4 in total

1.  Impact of patient- and disease-specific factors on SLNB in breast cancer patients. Are current guidelines justified?

Authors:  A Bembenek; J Fischer; H Albrecht; E Kemnitz; S Gretschel; U Schneider; S Dresel; P M Schlag
Journal:  World J Surg       Date:  2007-02       Impact factor: 3.352

Review 2.  Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies.

Authors:  Laleh Amiri-Kordestani; Agnes Basseville; Karen Kurdziel; Antonio Tito Fojo; Susan E Bates
Journal:  Drug Resist Updat       Date:  2012-03-29       Impact factor: 18.500

3.  Intraoperative imaging guidance for sentinel node biopsy in melanoma using a mobile gamma camera.

Authors:  Lynn T Dengel; Mitali J More; Patricia G Judy; Gina R Petroni; Mark E Smolkin; Patrice K Rehm; Stan Majewski; Mark B Williams; Craig L Slingluff
Journal:  Ann Surg       Date:  2011-04       Impact factor: 12.969

4.  Imaging of Fibroblast Activation Protein Alpha Expression in a Preclinical Mouse Model of Glioma Using Positron Emission Tomography.

Authors:  Darpan N Pandya; Akesh Sinha; Hong Yuan; Lysette Mutkus; Kristina Stumpf; Frank C Marini; Thaddeus J Wadas
Journal:  Molecules       Date:  2020-08-12       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.